Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06280950
Other study ID # DAIT CTOT-43
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 30, 2024
Est. completion date June 1, 2029

Study information

Verified date May 2024
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact Merideth Brown Shifflett, MS
Phone 240-627-3483
Email brownmeri@nih.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.


Description:

This study is a multicenter 2:1 randomized nonblinded phase II interventional clinical trial in liver transplant recipients. The primary objective is to determine the safety, efficacy, and tolerability of tacrolimus minimization and eventual withdrawal in conjunction with everolimus monotherapy to preserve renal function. Study subjects will undergo first reduction of tacrolimus with the addition of everolimus. If everolimus is tolerated, subjects will be randomized 2:1 into one of two interventional arms. The first interventional arm will under a stepwise reduction of tacrolimus and be on everolimus monotherapy for the remainder of the study. The second interventional arm will remain on the initial reduced tacrolimus dose and everolimus. If subjects prior to randomization are unable to tolerate everolimus, these subjects will be placed in the observational group. These subjects will stop taking everolimus and resume their immunosuppression therapy prior to study enrollment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 340
Est. completion date June 1, 2029
Est. primary completion date June 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject and/or legal guardian must be able to understand and provide informed consent 2. Adult recipient of first liver transplant alone (de novo) 3. Estimated glomerular filtration rate >=30 ml/min/1.73m^2 at enrollment using the CKD-EPI 2021 equation 4. Treatment with tacrolimus therapy, with or without mycophenolic acid derivatives and/or corticosteroids 5. Female subjects of childbearing potential with negative pregnancy test upon study entry 6. All subjects of reproductive potential agreeing to use contraception for the duration of the study 7. Previous vaccination or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, zoster (if >=19 years old), and 2019-nCoV (COVID-19) as outlined in the DAIT Vaccination Guideline Exclusion Criteria: 1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol 2. Active unresolved systemic viral, bacterial, fungal, or parasitic infection requiring oral or intravenous anti-infective therapy 3. History of autoimmune liver disease including autoimmune hepatitis, primary sclerosing cholangitis, and/or primary biliary cirrhosis, or other contraindications to drug withdrawal 4. History of non-hepatic autoimmune disease requiring current or future systemic immunosuppressive therapy other than per study protocol 5. History of Hepatic Artery Thrombosis or Portal Vein Thrombosis. 6. Chronic use of systemic glucocorticoids, biological immunomodulatory therapy, or other immunosuppressive agents other than per study protocol 7. History of hepatitis B or C virus infection with detectable viral PCR at enrollment 8. History of prior organ transplantation (liver or other type) 9. History of >= 2 biopsy-proven acute cellular rejection episodes of any severity, >=1 moderate to severe rejection episode (histologically defined or requiring lymphodepletion therapy), or >= 1 antibody- mediated rejection episode 10. Active treatment with any mTOR-inhibitor agent (everolimus, sirolimus) 11. Contraindication to treatment with everolimus (open wound or wound infection; urine protein: creatinine ratio > 0.5; significant pancytopenia (any of the following: WBC <1.5 K/uL or ANC <1000 cells/microL or actively being treated with GCSF; Hb <8.0; platelet count <50K); serum triglycerides > 1000 mg/dL; other per PI) 12. Abnormal liver function tests on study entry: Total Bilirubin (TB)>1.5 mg/dL and Direct Bilirubin (DB) >1.0 mg/dL, Alkaline Phosphatase (AP) >200 U/L, and Alanine Aminotransaminase (ALT)>60 U/L 13. Pregnant on enrollment or plan to become pregnant during the study period 14. Participation in another clinical trial that would interfere with this study's procedures and intervention: 1. Use of investigational biologic or drug (within 8 weeks of study enrollment) 2. Additional blood collection that would exceed research blood draw limits 3. Any other procedure or intervention, in the investigator's opinion would interfere with this study 15. Received live attenuated vaccine(s) within 2 months of enrollment 16. Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study 17. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Everolimus
The first step is the addition of everolimus to participants in this group pre-randomization. Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper. Participants taking prednisone will taper off prednisone by 6 months post-transplant. The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization.
Tacrolimus (continued reduction)
Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization. They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks. Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction
Tacrolimus (maintain 50% reduction)
- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
Everolimus
The first step is the addition of everolimus to participants in the interventional group pre-randomization. Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper. Participants taking prednisone will taper off prednisone by 6 months post-transplant. The second step is to continue on the reduced tacrolimus and everolimus regimen.

Locations

Country Name City State
United States Northwestern University (Site #: 71110) Chicago Illinois
United States Baylor Medical Center (Site #: 71153) Dallas Texas
United States Duke University Medical Center (Site #: 71139) Durham North Carolina
United States Icahn School of Medicine at Mount Sinai (Site #: 71115) New York New York
United States University of Pennsylvania (Site #: 71111) Philadelphia Pennsylvania
United States Mayo Clinic Hospital Arizona (Site #: 71144) Phoenix Arizona
United States University of Pittsburgh Medical Center (Site #: 71170) Pittsburgh Pennsylvania
United States University of California, San Francisco (Site #: 71108) San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change in estimated glomerular filtration rate (eGFR) by CKD-EPI 2021 equation. Between Cohorts INT-1 and INT-2 From Visit 2 to Visit 9 (12 months post-liver transplant)
Primary Proportion of subjects with treated Biopsy Proven Acute Rejection (tBPAR) per local pathology. Between cohorts INT-1 and INT-2 From Visit 2 to Visit 9 (12 months post-liver transplant)
Secondary Percent change in Estimated Glomerular Filtration Rate (eGFR) in Renal function From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Percentage of subjects with treated Biopsy Proven Acute Rejection (tBPAR) in Liver Function From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Changes in liver graft function: Total bilirubin From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Changes in liver graft function: Direct bilirubin From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Changes in liver graft function: Alanine Aminotransaminase (ALT) From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Changes in liver graft function: Aspartate Aminotransferase (AST) From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Changes in liver graft function: Alkaline Phosphatase From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Time to graft failure in liver function defined as relisting for transplantation, re-transplantation itself or death with failed graft From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Time to all-cause mortality From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects experiencing a Major Adverse Cardiac Event (MACE) From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects experiencing infection requiring hospitalization From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects experiencing any malignancy From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing severe Estimated Glomerular Filtration Rate (eGFR) deterioration >40 percent from baseline using the CKD-EPI 2021 equation From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing any major immunosuppressive therapy complications From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing new onset peripheral edema From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing new onset cytopenia deemed WBC <3.0x10^9 /L, Hb <8.0 g/dL, or platelets <50 x 10^9/L. From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing new onset oral/gastrointestinal ulcerations From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing new onset gastrointestinal symptoms (nausea, vomiting, abdominal pain, or diarrhea) related to everolimus therapy. From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing new onset pneumonitis From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing new onset hepatic artery thrombosis From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing other adverse events deemed From Visit 1 to Visit 11 (20 months post-liver transplant)
Secondary Proportion of subjects developing any adverse events related to everolimus therapy From Visit 1 to Visit 11 (20 months post-liver transplant)
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT01696331 - Text Messaging for Adherence in Adolescent Liver Transplant Recipients N/A
Recruiting NCT05051605 - Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
Recruiting NCT05940857 - Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Completed NCT01598987 - Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. Phase 3
Active, not recruiting NCT05074160 - OCS Liver Perfusion (OLP) Post-Approval Registry
Completed NCT05087550 - Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
Recruiting NCT04836923 - LIFT Intervention in Liver Transplant Candidates N/A
Not yet recruiting NCT03666689 - Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
Not yet recruiting NCT06088758 - Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool N/A
Terminated NCT01230502 - Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation N/A
Completed NCT00171509 - Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients Phase 4
Not yet recruiting NCT06254248 - Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT06075745 - Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates Phase 2
Completed NCT02057484 - A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
Active, not recruiting NCT03577431 - Liver Transplantation With Tregs at MGH Phase 1/Phase 2
Recruiting NCT06342557 - Transitional ePRO Diary Liver
Not yet recruiting NCT04265157 - Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry